Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

348 ARTÍCULOS , VIENDO DEL 166 AL 180

Entorhinal cortex: a good biomarker of mild cognitive impairment and mild Alzheimer's disease

Zhou M, Zhang F, Zhao L, Qian J, Dong C.

Rev Neurosci. 2016 Feb;27(2):185-95. doi: 10.1515/revneuro-2015-0019.

Detection and Differentiation of Frontotemporal Dementia and Related Disorders From Alzheimer Disease Using the Montreal Cognitive Assessment

Coleman KK, Coleman BL, MacKinley JD, Pasternak SH, Finger EC.

Alzheimer Dis Assoc Disord. 2016 Jul-Sep;30(3):258-63. doi: 10.1097/WAD.0000000000000119.

Recent Updates on the Association Between Alzheimer's Disease and Vascular Dementia

Ashraf GM, Chibber S, Mohammad, Zaidi SK, Tabrez S, Ahmad A, Shakil S, Mushtaq G, Baeesa SS, Kamal MA.

Med Chem. 2016;12(3):226-37. doi: 10.2174/1573406411666151030111820.

Agitation and Irritability in Alzheimer's Disease: Evidenced-Based Treatments and the Black-Box Warning

Koenig AM, Arnold SE, Streim JE.

Curr Psychiatry Rep. 2016 Jan;18(1):3. doi: 10.1007/s11920-015-0640-7.

Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial

Schneider LS, Frangakis C, Drye LT, Devanand DP, Marano CM, Mintzer J, Mulsant BH, Munro CA, Newell JA, Pawluczyk S, Pelton G, Pollock BG, Porsteinsson AP, Rabins PV, Rein L, Rosenberg PB, Shade D, Weintraub D, Yesavage J, Lyketsos CG; CitAD Research Group.

Am J Psychiatry. 2016 May 1;173(5):465-72. doi: 10.1176/appi.ajp.2015.15050648. Epub 2016 Jan 15.

Neuroimaging of hippocampal atrophy in early recognition of Alzheimer's disease--a critical appraisal after two decades of research

Schröder J, Pantel J.

Psychiatry Res Neuroimaging. 2016 Jan 30;247:71-8. doi: 10.1016/j.pscychresns.2015.08.014.

Progressive Language Impairment in an English-Italian Bilingual Woman With Alzheimer Disease: An 18-Month Follow-up

D'Antonio F, Imbriano L, Campanelli A, de Lena C, Trebbastoni A.

Alzheimer Dis Assoc Disord. 2016 Oct-Dec;30(4):354-356. doi: 10.1097/WAD.0000000000000139.

Predictors of cognitive decline and treatment response in a clinical trial on suspected prodromal Alzheimer's disease

Teipel SJ, Cavedo E, Grothe MJ, Lista S, Galluzzi S, Colliot O, Chupin M, Bakardjian H, Dormont D, Dubois B, Hampel H; Hippocampus Study Group.

Neuropharmacology. 2016 Sep;108:128-35. doi: 10.1016/j.neuropharm.2016.02.005. Epub 2016 Feb 10.

Amyloid PET Screening for Enrichment of Early-Stage Alzheimer Disease Clinical Trials: Experience in a Phase 1b Clinical Trial

Sevigny J, Suhy J, Chiao P, Chen T, Klein G, Purcell D, Oh J, Verma A, Sampat M, Barakos J.

Alzheimer Dis Assoc Disord. 2016 Jan-Mar;30(1):1-7. doi: 10.1097/WAD.0000000000000144.

Course and Determinants of Anosognosia in Alzheimer's Disease: A 12-Month Follow-up

Turró-Garriga O, Garre-Olmo J, Calvó-Perxas L, Reñé-Ramírez R, Gascón-Bayarri J, Conde-Sala JL.

J Alzheimers Dis. 2016;51(2):357-66. doi: 10.3233/JAD-150706.

Frontal Lobe Degeneration in Adults with Down Syndrome and Alzheimer's Disease: A Review

Fonseca LM, Yokomizo JE, Bottino CM, Fuentes D.

Dement Geriatr Cogn Disord. 2016;41(3-4):123-36. doi: 10.1159/000442941. Epub 2016 Feb 19.

On cognitive ecology and the environmental factors that promote Alzheimer disease: lessons from Octodon degus (Rodentia: Octodontidae)

Rivera DS, Inestrosa NC, Bozinovic F.

Biol Res. 2016 Feb 20;49:10. doi: 10.1186/s40659-016-0074-7.

Could Better Phenotyping Small Vessel Disease Provide New Insights into Alzheimer Disease and Improve Clinical Trial Outcomes?

Marnane M, Hsiung GY.

Curr Alzheimer Res. 2016;13(7):750-63. doi: 10.2174/1567205013666160222112634.

Gait dyspraxia as a clinical marker of cognitive decline in Down syndrome: A review of theory and proposed mechanisms

Anderson-Mooney AJ, Schmitt FA, Head E, Lott IT, Heilman KM.

Brain Cogn. 2016 Apr;104:48-57. doi: 10.1016/j.bandc.2016.02.007. Epub 2016 Feb 27.

Optimal nonpharmacological management of agitation in Alzheimer's disease: challenges and solutions

Millán-Calenti JC, Lorenzo-López L, Alonso-Búa B, de Labra C, González-Abraldes I, Maseda A.

Clin Interv Aging. 2016 Feb 22;11:175-84. doi: 10.2147/CIA.S69484. eCollection 2016.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias